NEW YORK, NY--(Marketwired - Nov 27, 2015) - Daxor Corporation (
Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012. If the company was still reporting as a 1934 Act Company, our unaudited results for the nine months ended September 30, 2015 would have been net income of $6,120,660 or $1.57 per share. The Company had $21,356,338 of margin loans payable at December 31, 2014 and $4,210,637 of margin loans payable at September 30, 2015. However, since the company reports as an investment company, we are reporting a decrease in net assets for the nine month period ended September 30, 2015.
At September 30, 2015, the Company had net assets of $19,020,522 or $4.93 per share versus net assets of $24,580,735 or $6.16 per share at December 31, 2014.
Net assets decreased by $(5,560,213) during the nine months ended September 30, 2015. The Company had dividend income of $899,450, net realized gains from investments of $11,481,412 and net realized gains from options of $1,008,979. These amounts were offset by a net change in the unrealized depreciation on investments of $(9,367,789), realized losses on the sale of short positions of $(4,889,755) and a net change to the unrealized depreciation on the Company's Operating Division of $(2,814,708). The net change in the unrealized depreciation on investments of $(9,367,789) includes a charge of $(10,836,916) which is the decrease in the net fair value over cost of the Company's securities portfolio from December 31, 2014 to September 30, 2015.
The Company's investment policy is to maintain a minimum of 80% of the value of its portfolio in electric utilities. At September 30, 2015, investments in electric utilities made up 89.5% of the value of the Company's portfolio. Dividends from the Company's investments in electric utilities made up 81.8% of the Company's total dividends received for the nine months ended September 30, 2015. The Company is receiving dividend income on 40 of the 46 common and preferred stocks in its investment portfolio at September 30, 2015.
Michael Feldschuh, the Executive Vice-President of Daxor, stated, "Our trailing financial results reinforce our conviction that current restructuring of operations toward efficiency and profitability which have begun in earnest in the past quarter will be crucial to generating positive results in the coming fiscal year. We have identified important opportunities to leverage our sales efforts and will continue to pursue partnerships with entities that are promising as we add resources and rigor to this important effort."
Dr. Joseph Feldschuh, the CEO of Daxor, added the following: "The recent published results of a study from the Mayo Clinic concerning the use of the blood volume analyzer in heart failure lends strong support to the concept that blood volume measurement provides a significantly more accurate assessment of the blood volume derangements observed in heart failure than the current limited testing. The precise knowledge of a patient's blood volume is essential for optimally treating critically ill medical and surgical patients. Our goal is to make our method of blood volume measurement the standard of care for any patient experiencing a blood volume derangement."
The Company is continuing its stock buyback program and plans to declare and pay a dividend in December of 2015.
Contact Information: Daxor Corporation: Michael Feldschuh (212)330-8500 (Executive Vice President) mfeldschuh@daxor.com David Frankel 212-330-8504 (Chief Financial Officer) dfrankel@daxor.com Diane Meegan 212-330-8512 (Investor Relations) dmeegan@daxor.com
